Expression of MASTL (Greatwall) associates with good prognosis and response to radiotherapy in pharyngeal squamous cell carcinoma

Head and neck squamous cell carcinomas (HNSCCs) are highly heterogeneous in both disease progression and treatment outcome, with hardly any molecular biomarker in clinical practice. Thus, the aim of this study was to investigate the potential prognostic and predictive value of MASTL/Greatwall, a mit...

ver descrição completa

Detalhes bibliográficos
Autores: Pozo-Agundo, Esperanza, Álvarez-González, Miguel, Rivera-García, Israel, García-de-la-Fuente, Vanessa, Martino, Alba de, Tejedor, Juan Ramón, Vicente, Juan Carlos de, Rodrigo Tapia, Juan Pablo, García-Pedrero, Juana M., Álvarez-Fernández, Mónica
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Recursos:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/391241
Acesso em linha:http://hdl.handle.net/10261/391241
Access Level:acceso abierto
Palavra-chave:MASTL
Prognosis
Head and neck cancer
Radiotherapy
Pharyngeal squamous cell carcinoma
p21
id ES_096924a89af69094eecd602256ab0a36
oai_identifier_str oai:digital.csic.es:10261/391241
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Expression of MASTL (Greatwall) associates with good prognosis and response to radiotherapy in pharyngeal squamous cell carcinoma
title Expression of MASTL (Greatwall) associates with good prognosis and response to radiotherapy in pharyngeal squamous cell carcinoma
spellingShingle Expression of MASTL (Greatwall) associates with good prognosis and response to radiotherapy in pharyngeal squamous cell carcinoma
Pozo-Agundo, Esperanza
MASTL
Prognosis
Head and neck cancer
Radiotherapy
Pharyngeal squamous cell carcinoma
p21
title_short Expression of MASTL (Greatwall) associates with good prognosis and response to radiotherapy in pharyngeal squamous cell carcinoma
title_full Expression of MASTL (Greatwall) associates with good prognosis and response to radiotherapy in pharyngeal squamous cell carcinoma
title_fullStr Expression of MASTL (Greatwall) associates with good prognosis and response to radiotherapy in pharyngeal squamous cell carcinoma
title_full_unstemmed Expression of MASTL (Greatwall) associates with good prognosis and response to radiotherapy in pharyngeal squamous cell carcinoma
title_sort Expression of MASTL (Greatwall) associates with good prognosis and response to radiotherapy in pharyngeal squamous cell carcinoma
dc.creator.none.fl_str_mv Pozo-Agundo, Esperanza
Álvarez-González, Miguel
Rivera-García, Israel
García-de-la-Fuente, Vanessa
Martino, Alba de
Tejedor, Juan Ramón
Vicente, Juan Carlos de
Rodrigo Tapia, Juan Pablo
García-Pedrero, Juana M.
Álvarez-Fernández, Mónica
author Pozo-Agundo, Esperanza
author_facet Pozo-Agundo, Esperanza
Álvarez-González, Miguel
Rivera-García, Israel
García-de-la-Fuente, Vanessa
Martino, Alba de
Tejedor, Juan Ramón
Vicente, Juan Carlos de
Rodrigo Tapia, Juan Pablo
García-Pedrero, Juana M.
Álvarez-Fernández, Mónica
author_role author
author2 Álvarez-González, Miguel
Rivera-García, Israel
García-de-la-Fuente, Vanessa
Martino, Alba de
Tejedor, Juan Ramón
Vicente, Juan Carlos de
Rodrigo Tapia, Juan Pablo
García-Pedrero, Juana M.
Álvarez-Fernández, Mónica
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Agencia Estatal de Investigación (España)
Ministerio de Ciencia, Innovación y Universidades (España)
Instituto de Salud Carlos III
European Commission
Asociación Española Contra el Cáncer
Principado de Asturias
Fundación para el Fomento en Asturias de la Investigación Científica Aplicada y la Tecnología
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv MASTL
Prognosis
Head and neck cancer
Radiotherapy
Pharyngeal squamous cell carcinoma
p21
topic MASTL
Prognosis
Head and neck cancer
Radiotherapy
Pharyngeal squamous cell carcinoma
p21
description Head and neck squamous cell carcinomas (HNSCCs) are highly heterogeneous in both disease progression and treatment outcome, with hardly any molecular biomarker in clinical practice. Thus, the aim of this study was to investigate the potential prognostic and predictive value of MASTL/Greatwall, a mitotic kinase also involved in PI3K-mTOR signaling and the DNA damage response, in HNSCC.
publishDate 2025
dc.date.none.fl_str_mv 2025
2025
2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/391241
url http://hdl.handle.net/10261/391241
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv #PLACEHOLDER_PARENT_METADATA_VALUE#
info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2020-117236RB-I00
The underlying dataset has been published as supplementary material of the article in the publisher platform at DOI 10.1016/j.tranon.2025.102417
https://doi.org/10.1016/j.tranon.2025.102417
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403104327237632
spelling Expression of MASTL (Greatwall) associates with good prognosis and response to radiotherapy in pharyngeal squamous cell carcinomaPozo-Agundo, EsperanzaÁlvarez-González, MiguelRivera-García, IsraelGarcía-de-la-Fuente, VanessaMartino, Alba deTejedor, Juan RamónVicente, Juan Carlos deRodrigo Tapia, Juan PabloGarcía-Pedrero, Juana M.Álvarez-Fernández, MónicaMASTLPrognosisHead and neck cancerRadiotherapyPharyngeal squamous cell carcinomap21Head and neck squamous cell carcinomas (HNSCCs) are highly heterogeneous in both disease progression and treatment outcome, with hardly any molecular biomarker in clinical practice. Thus, the aim of this study was to investigate the potential prognostic and predictive value of MASTL/Greatwall, a mitotic kinase also involved in PI3K-mTOR signaling and the DNA damage response, in HNSCC.MASTL expression was evaluated by immunohistochemistry in a cohort of 346 surgically treated HPV-negative pharyngeal and laryngeal squamous cell carcinoma patients, as well as in pre-treatment biopsies from a separate cohort of 64 patients treated with induction chemotherapy (ICT). In addition, MASTL mRNA expression was analyzed in 135 patients from The Cancer Genome Atlas (TCGA) database.High MASTL expression was significantly associated with improved disease-specific survival (DSS) (P = 0.029), specifically in well-differentiated pharyngeal squamous cell carcinoma (PSCC) tumors (P = 0.002). Notably, this association was restricted to patients who received adjuvant radiotherapy (RT) (P = 0.009). Consistently, a similar correlation was found at the mRNA level in PSCC tumors from the TCGA dataset. Moreover, the combined expression of MASTL and p21 was significantly associated with better DSS, specifically among patients receiving RT (P = 0.014). Multivariate Cox regression analysis further confirmed that high MASTL expression was independently associated with favorable prognosis in patients who received post-operative RT (HR= 0.65; 95 % CI: 0.45–0.94; P = 0.021).Collectively, these findings unprecedentedly revealed the association between high MASTL expression and favorable outcome in advanced HPV-negative PSCC, in marked contrast to previous reports in other tumor types. Importantly, MASTL expression emerges as an independent predictor of good prognosis in RT-treated PSCC patients.This study was supported by grants from the MCIN/AEI (PID2020–117236RB-I00 to MAF), from Instituto de Salud Carlos III (PI19/00560, PI22/00167 to JMGP; PI19/01255 to JCdV) and CIBERONC (CB16/12/00390 to JPR). M.A.F was supported by the Asociación Española contra el Cáncer (AECC; 2019/INVES19001ALVA). E.P.A is a recipient of a PFIS predoctoral fellowship from ISCIII (FI20/00064) and M.A.G is recipient of a Severo Ochoa predoctoral fellowship from the Principado de Asturias (BP21–205). Additional funding was provided through the grant “Ayudas para Grupos de Investigación de Organismos del Principado de Asturias 2021–2023″ (IDI/2021/000079), funded by Principado de Asturias through FICYT and the FEDER Funding Program from the European Union.Peer reviewedElsevierAgencia Estatal de Investigación (España)Ministerio de Ciencia, Innovación y Universidades (España)Instituto de Salud Carlos IIIEuropean CommissionAsociación Española Contra el CáncerPrincipado de AsturiasFundación para el Fomento en Asturias de la Investigación Científica Aplicada y la TecnologíaConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202520252025info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/391241reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Inglés#PLACEHOLDER_PARENT_METADATA_VALUE#info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2020-117236RB-I00The underlying dataset has been published as supplementary material of the article in the publisher platform at DOI 10.1016/j.tranon.2025.102417https://doi.org/10.1016/j.tranon.2025.102417Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3912412026-05-22T06:33:51Z
score 15,198674

Registos relacionados